Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSSM-001 in Steroid-Refractory Acute GVHD
NCT05443464Phase 1Withdrawn
- Sponsor
- Ossium Health
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, open-label trial of ossm-001 in Acute Graft-Versus-Host Disease (aGvHD) (4 arms), sponsored by Ossium Health. Primary endpoint: Safety events at 16 weeks. Planned start Jun 2023; status: withdrawn.
02
Drugs
ossm-001
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05443464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443464.